HTG Receives US Patent for HTG EdgeSeq Chemistry Coupling Quantitative Nuclease Protection With Next-Generation-SequencingContinue reading
Senestech signs exclusive licensing agreement with Neogen
AZBio Member Senestech has entered into an exclusive licensing agreement with Neogen to manufacture and market a rodent control product that uses fertility control to manage rat populations.Continue reading
Slepian-Led Startup Targets Paradigm Shift in Heart Valve Surgery
University Relations – Communications | June 11, 2014Dr. Marvin J. Slepian, UA professor of medicine and biomedical engineering and a cardiologist at the UA Sarver Heart Center, is the founding CEO of PolyNova.Continue reading
TGen and Arizona Community Foundation partner to support ASU football concussion research
TGen Concussion Research Fund is first under ACF’s new Jerry Colangelo Center for Sports PhilanthropyContinue reading
HTG Launches an Automated, Sequencing-Based miRNA Whole Transcriptome Digital Gene Expression Assay for Challenging Sample Types
TUCSON, AZ– – Today HTG Molecular Diagnostics announced the availability of HTG EdgeSeq miRNA Whole Transcriptome Assay for measuring the expression of 2,275 human microRNAs (miRNAs) described in the miRBase v20 database.Continue reading
New therapy for pancreatic cancer patients shows promising results
TGen-Scottsdale Healthcare lead international clinical trials in advance of FDA application for NAPOLI-1Continue reading
ASU receives Gates grant for research in global health
Arizona State University has been awarded a Grand Challenges Explorations grant, an initiative funded by the Bill & Melinda Gates Foundation. Biodesign Institute researcher Shengxi Chen will pursue a global health and innovation project to design a better, next-generation condom.Continue reading
Insys Therapeutics Cannabiodol Receives Orphan Drug Status for Lennox-Gastaut syndrome
On June 2, 2014 the FDA designated Insys Therapeutics’ (INSY) cannabidiol an Orphan Drug for the treatment of Lennox-Gastaut syndrome. (See FDA Site) The firm submitted its Type II Drug Master File to the FDA on May29. A copy of the Insys release on the filing is provided below.
ASU embarks on $9 million next phase of an effort to assess rapidly an absorbed radiation dose
Arizona State University’s Biodesign Institute announced today it is entering a new, $9 million phase of a multi-million, multi-institutional development project to produce a diagnostic test to measure rapidly an individual’s level of absorption of ionizing radiation in the event of an unplanned radiological or nuclear event. Continue reading
BioPharm Insight: Regenesis now sees exit as sale to strategic player in 12 to 24 months – CEO
Regenesis Biomedical, a Scottsdale, Arizona-based medical device company, now sees a sale to a strategic in 2015 or 2016 as its likely exit, said CEO Scott Brooks.Continue reading